IDEAS home Printed from https://ideas.repec.org/r/chy/respap/138chedp.html
   My bibliography  Save this item

A social tariff for EuroQol: results from a UK general population survey

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Nick Bansback & Huiying Sun & Daphne P. Guh & Xin Li & Bohdan Nosyk & Susan Griffin & Paul G. Barnett & Aslam H. Anis, 2008. "Impact of the recall period on measuring health utilities for acute events," Health Economics, John Wiley & Sons, Ltd., vol. 17(12), pages 1413-1419.
  2. James Mahon & Lindsay Claxton & Hannah Wood, 2016. "Modelling the cost-effectiveness of human milk and breastfeeding in preterm infants in the United Kingdom," Health Economics Review, Springer, vol. 6(1), pages 1-8, December.
  3. Gisela Kobelt & J. Berg & P. Lindgren, 2006. "Costs and quality of life in multiple sclerosis in The Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 55-64, July.
  4. Gisela Kobelt & J. Berg & P. Lindgren & G. Izquierdo & O. Sánchez-Soliño & J. Pérez-Miranda & M. Casado, 2006. "Costs and quality of life of multiple sclerosis in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 65-74, July.
  5. Erika Laranjeira & Helena Szrek, 2016. "Going beyond life expectancy in assessments of health systems’ performance: life expectancy adjusted by perceived health status," International Journal of Health Economics and Management, Springer, vol. 16(2), pages 133-161, June.
  6. Richard Norman & Paula Cronin & Rosalie Viney & Madeleine King & Deborah Street & John Brazier & Julie Ratcliffe, 2007. "Valuing EQ-5D health states: A review and analysis, CHERE Working Paper 2007/9," Working Papers 2007/9, CHERE, University of Technology, Sydney.
  7. Aki Tsuchiya & Shunya Ikeda & Naoki Ikegami & Shuzo Nishimura & Ikuro Sakai & Takashi Fukuda & Chisato Hamashima & Akinori Hisashige & Makoto Tamura, 2002. "Estimating an EQ‐5D population value set: the case of Japan," Health Economics, John Wiley & Sons, Ltd., vol. 11(4), pages 341-353, June.
  8. R. McQueen & Samuel Ellis & David Maahs & Heather Anderson & Kavita Nair & Anne Libby & Jonathan Campbell, 2014. "Association Between Glycated Hemoglobin and Health Utility for Type 1 Diabetes," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 7(2), pages 197-205, June.
  9. Jing Chen & Carlos K H Wong & Sarah M McGhee & Polly K P Pang & Wai-Cho Yu, 2014. "A Comparison between the EQ-5D and the SF-6D in Patients with Chronic Obstructive Pulmonary Disease (COPD)," PLOS ONE, Public Library of Science, vol. 9(11), pages 1-9, November.
  10. Richard Holland & Richard D Smith & Ian Harvey & Louise Swift & Elizabeth Lenaghan, 2004. "Assessing quality of life in the elderly: a direct comparison of the EQ‐5D and AQoL," Health Economics, John Wiley & Sons, Ltd., vol. 13(8), pages 793-805, August.
  11. Blumenschein, K. & Johannesson, M., 1996. "The authors reply," Health Policy, Elsevier, vol. 37(3), pages 201-204, September.
  12. Adrian Bagust & Sophie Beale, 2005. "Modelling EuroQol health‐related utility values for diabetic complications from CODE‐2 data," Health Economics, John Wiley & Sons, Ltd., vol. 14(3), pages 217-230, March.
  13. Petrie, Dennis & Doran, Chris & Shakeshaft, Anthony & Sanson-Fisher, Rob, 2008. "The relationship between alcohol consumption and self-reported health status using the EQ5D: Evidence from rural Australia," Social Science & Medicine, Elsevier, vol. 67(11), pages 1717-1726, December.
  14. Gisela Kobelt & J. Berg & P. Lindgren, 2006. "Costs and quality of life in multiple sclerosis in The Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 55-64, July.
  15. Suzanne Robinson, 2011. "Test–retest reliability of health state valuation techniques: the time trade off and person trade off," Health Economics, John Wiley & Sons, Ltd., vol. 20(11), pages 1379-1391, November.
  16. Karl Claxton & Steve Martin & Marta Soares & Nigel Rice & Eldon Spackman & Sebastian Hinde & Nancy Devlin & Peter C Smith & Mark Sculpher, 2013. "Methods for the estimation of the NICE cost effectiveness threshold," Working Papers 081cherp, Centre for Health Economics, University of York.
  17. Susan Cleary & Gavin Mooney & Di McIntyre, 2010. "Equity and efficiency in HIV‐treatment in South Africa: the contribution of mathematical programming to priority setting," Health Economics, John Wiley & Sons, Ltd., vol. 19(10), pages 1166-1180, October.
  18. Garry R. Barton & Tracey H. Sach & Anthony J. Avery & Claire Jenkinson & Michael Doherty & David K. Whynes & Kenneth R. Muir, 2008. "A comparison of the performance of the EQ‐5D and SF‐6D for individuals aged ≥ 45 years," Health Economics, John Wiley & Sons, Ltd., vol. 17(7), pages 815-832, July.
  19. McNamee, Paul, 2007. "What difference does it make? The calculation of QALY gains from health profiles using patient and general population values," Health Policy, Elsevier, vol. 84(2-3), pages 321-331, December.
  20. Björn Sund & Mikael Svensson, 2018. "Estimating a constant WTP for a QALY—a mission impossible?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(6), pages 871-880, July.
  21. N J Devlin & P Hansen & P Kind & A H Williams, 2000. "The health state preferences and logistical inconsistencies of New Zealanders: a tale of two tariffs," Working Papers 180chedp, Centre for Health Economics, University of York.
  22. Michael Falk Hvidberg & Mónica Hernández Alava, 2023. "Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA," PharmacoEconomics, Springer, vol. 41(10), pages 1287-1388, October.
  23. José‐María Abellán‐Perpiñán & José‐Luis Pinto‐Prades & Ildefonso Méndez‐Martínez & Xabier Badía‐Llach, 2006. "Towards a better QALY model," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 665-676, July.
  24. José Luis Pinto‐Prades & Neil McHugh & Cam Donaldson & Sarkis Manoukian, 2019. "Sequence effects in time trade‐off valuation of hypothetical health states," Health Economics, John Wiley & Sons, Ltd., vol. 28(11), pages 1308-1319, November.
  25. John Yfantopoulos & Athanasios Chantzaras, 2020. "Health-related quality of life and health utilities in insulin-treated type 2 diabetes: the impact of related comorbidities/complications," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(5), pages 729-743, July.
  26. Gisela Kobelt & Jenny Berg & Peter Lindgren & M. Battaglia & C. Lucioni & A. Uccelli, 2006. "Costs and quality of life of multiple sclerosis in Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 45-54, July.
  27. Madlaina Costa-Scharplatz & Björn Ställberg & Pankaj Goyal & Yumi Asukai & Jean-Bernard Gruenberger & David Price, 2015. "Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden," Applied Health Economics and Health Policy, Springer, vol. 13(6), pages 637-645, December.
  28. Garry Barton & Tracey Sach & Michael Doherty & Anthony Avery & Claire Jenkinson & Kenneth Muir, 2008. "An assessment of the discriminative ability of the EQ-5D index , SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(3), pages 237-249, August.
  29. Marian Sorin Paveliu & Elena Olariu & Raluca Caplescu & Yemi Oluboyede & Ileana-Gabriela Niculescu-Aron & Simona Ernu & Luke Vale, 2021. "Estimating an EQ-5D-3L Value Set for Romania Using Time Trade-Off," IJERPH, MDPI, vol. 18(14), pages 1-16, July.
  30. Lyn Murphy & William Maguire, 2011. "Applying mixed methods research in evaluating clinical trials," Qualitative Research in Accounting & Management, Emerald Group Publishing Limited, vol. 8(1), pages 72-90, April.
  31. Teresa C. O. Tsui & Kelvin K. W. Chan & Feng Xie & Eleanor M. Pullenayegum, 2024. "Creating a Multiply Imputed Value Set for the EQ-5D-5L in Canada: State-Level Misspecification Terms Are Needed to Characterize Parameter Uncertainty Correctly," Medical Decision Making, , vol. 44(4), pages 405-414, May.
  32. G. Kobelt & B. Jönsson, 2008. "The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 95-106, January.
  33. Nick Bansback & Huiying Sun & Daphne P. Guh & Xin Li & Bohdan Nosyk & Susan Griffin & Paul G. Barnett & Aslam H. Anis, 2008. "Impact of the recall period on measuring health utilities for acute events," Health Economics, John Wiley & Sons, Ltd., vol. 17(12), pages 1413-1419, December.
  34. Gisela Kobelt & Jenny Berg & Peter Lindgren & W. Elias & P. Flachenecker & M. Freidel & N. König & V. Limmroth & E. Straube, 2006. "Costs and quality of life of multiple sclerosis in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 34-44, July.
  35. MerriKay Oleen-Burkey & Jane Castelli-Haley & Maureen Lage & Kenneth Johnson, 2012. "Burden of a Multiple Sclerosis Relapse," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 5(1), pages 57-69, March.
  36. Brazier, John & Roberts, Jennifer & Deverill, Mark, 2002. "The estimation of a preference-based measure of health from the SF-36," Journal of Health Economics, Elsevier, vol. 21(2), pages 271-292, March.
  37. Gisela Kobelt & Jenny Berg & Peter Lindgren & M. Battaglia & C. Lucioni & A. Uccelli, 2006. "Costs and quality of life of multiple sclerosis in Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 45-54, July.
  38. Laura González-Suñer & Cristina Carbonell-Duacastella & Ignacio Aznar-Lou & Maria Rubio-Valera & Maria Iglesias-González & Maria Teresa Peñarrubia-María & Montserrat Gil-Girbau & Antoni Serrano-Blanco, 2021. "Use of Mental Health Services for Patients Diagnosed with Major Depressive Disorders in Primary Care," IJERPH, MDPI, vol. 18(3), pages 1-13, January.
  39. Karen Gerard & Katharine Johnston & Jackie Brown, 1999. "The role of a pre‐scored multi‐attribute health classification measure in validating condition‐specific health state descriptions," Health Economics, John Wiley & Sons, Ltd., vol. 8(8), pages 685-699, December.
  40. Emma McIntosh, 2006. "Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework," PharmacoEconomics, Springer, vol. 24(9), pages 855-868, September.
  41. Lyttkens, Carl Hampus & Gerdtham, Ulf-G. & Tinghög, Gustav, 2018. "Do We Know What We Are Doing? An Exploratory Study on Swedish Health Economists and the EQ-5D," Working Papers 2018:40, Lund University, Department of Economics.
  42. Andrew M Jones, 1995. "A microeconometric analysis of smoking in the UK health and lifestyle survey," Working Papers 139chedp, Centre for Health Economics, University of York.
  43. A. Enrique & J. Burke & D. Richards & L. Timulak, 2019. "Quality of Life Outcomes in Internet-Delivered (Space from Depression) Treatment for Depression," Applied Research in Quality of Life, Springer;International Society for Quality-of-Life Studies, vol. 14(5), pages 1301-1313, November.
  44. Laura Bojke & Edward Hornby & Mark Sculpher, 2007. "A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic Fundoplication) in the Treatment of GORD," PharmacoEconomics, Springer, vol. 25(10), pages 829-841, October.
  45. Kobelt, G., 2013. "Health Economics: An Introduction to Economic Evaluation," Monographs, Office of Health Economics, number 000004.
  46. Dennis Petrie & Chris Doran & Anthony Shakeshaft & Rob Sanson-Fisher, 2007. "The relationship between alcohol consumption and self-reported health status using the EQ5D," Dundee Discussion Papers in Economics 204, Economic Studies, University of Dundee.
  47. Gisela Kobelt & Jenny Berg & Peter Lindgren & Andrea Gerfin & J. Lutz, 2006. "Costs and quality of life of multiple sclerosis in Switzerland," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 86-95, July.
  48. Gisela Kobelt & Jenny Berg & Peter Lindgren & Carlotta Plesnilla & Ulf Baumhackl & Thomas Berger & Harald Kolleger & Karl Vass, 2006. "Costs and quality of life of multiple sclerosis in Austria," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 14-23, July.
  49. Carmen Selva-Sevilla & Paula Ferrara & Manuel Gerónimo-Pardo, 2020. "Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(4), pages 649-662, June.
  50. An Tran-Duy & Annelies Boonen & Wietske Kievit & Piet Riel & Mart Laar & Johan Severens, 2014. "Modelling Outcomes of Complex Treatment Strategies Following a Clinical Guideline for Treatment Decisions in Patients with Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 32(10), pages 1015-1028, October.
  51. Helen Campbell & Sue Tait & Linda Sharples & Noreen Caine & Timothy Gray & Peter Schofield & Martin Buxton, 2005. "Trial-based cost-utility comparison of percutaneous myocardial laser revascularisation and continued medical therapy for treatment of refractory angina pectoris," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(4), pages 288-297, December.
  52. Gisela Kobelt & Jenny Berg & Peter Lindgren & Carlotta Plesnilla & Ulf Baumhackl & Thomas Berger & Harald Kolleger & Karl Vass, 2006. "Costs and quality of life of multiple sclerosis in Austria," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 14-23, July.
  53. Danielle Brunenberg & Gwenn Wetzels & Patricia Nelemans & Carmen Dirksen & Johan Severens & Henri Stoffers & Jan Schouten & Martin Prins & Peter Leeuw & Manuela Joore, 2007. "Cost Effectiveness of an Adherence-Improving Programme in Hypertensive Patients," PharmacoEconomics, Springer, vol. 25(3), pages 239-251, March.
  54. James Love-Koh & Susan Griffin & Edward Kataika & Paul Revill & Sibusiso Sibandze & Simon Walker & Jessica Ochalek & Mark Sculpher & Matthias Arnold, 2019. "Economic analysis for health benefits package design," Working Papers 165cherp, Centre for Health Economics, University of York.
  55. Adam Oliver, 2013. "Testing Procedural Invariance In The Context Of Health," Health Economics, John Wiley & Sons, Ltd., vol. 22(3), pages 272-288, March.
  56. Gisela Kobelt & Jenny Berg & P. Lindgren & J. Kerrigan & N. Russell & R. Nixon, 2006. "Costs and quality of life of multiple sclerosis in the United Kingdom," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 96-104, July.
  57. Rachel A. Elliott & Lukasz Tanajewski & Georgios Gkountouras & Anthony J. Avery & Nick Barber & Rajnikant Mehta & Matthew J. Boyd & Asam Latif & Antony Chuter & Justin Waring, 2017. "Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal," PharmacoEconomics, Springer, vol. 35(12), pages 1237-1255, December.
  58. Lieven Annemans & Mélanie Brignone & Sylvain Druais & Ann Pauw & Aline Gauthier & Koen Demyttenaere, 2014. "Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium," PharmacoEconomics, Springer, vol. 32(5), pages 479-493, May.
  59. Lena Lundberg & Magnus Johannesson & Dag G.L. Isacson & Lars Borgquist, 1999. "The Relationship between Health-state Utilities and the SF-12 in a General Population," Medical Decision Making, , vol. 19(2), pages 128-140, April.
  60. Hedwig Blommestein & Nigel Armstrong & Steve Ryder & Sohan Deshpande & Gill Worthy & Caro Noake & Rob Riemsma & Jos Kleijnen & Johan Severens & Maiwenn Al, 2016. "Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene," PharmacoEconomics, Springer, vol. 34(1), pages 23-31, January.
  61. Gisela Kobelt & J. Berg & P. Lindgren & G. Izquierdo & O. Sánchez-Soliño & J. Pérez-Miranda & M. Casado, 2006. "Costs and quality of life of multiple sclerosis in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 65-74, July.
  62. Xavier Badia & Montserrat Roset & Michael Herdman & Paul Kind, 2001. "A Comparison of United Kingdom and Spanish General Population Time Trade-off Values for EQ-5D Health States," Medical Decision Making, , vol. 21(1), pages 7-16, February.
  63. Shaheen, Rubina & Lindholm, Lars, 2006. "Quality of life among pregnant women with chronic energy deficiency in rural Bangladesh," Health Policy, Elsevier, vol. 78(2-3), pages 128-134, October.
  64. Yvette Edelaar-Peeters & Anne M. Stiggelbout & Wilbert B. Van Den Hout, 2014. "Qualitative and Quantitative Analysis of Interviewer Help Answering the Time Tradeoff," Medical Decision Making, , vol. 34(5), pages 655-665, July.
  65. Bram Roudijk & A. Rogier T. Donders & Peep F. M. Stalmeier, 2019. "Cultural Values: Can They Explain Differences in Health Utilities between Countries?," Medical Decision Making, , vol. 39(5), pages 605-616, July.
  66. Nancy J. Devlin & Richard Brooks, 2017. "EQ-5D and the EuroQol Group: Past, Present and Future," Applied Health Economics and Health Policy, Springer, vol. 15(2), pages 127-137, April.
  67. R. Hernández & D. Jenkinson & L. Vale & B. Cuthbertson, 2014. "Economic evaluation of nurse-led intensive care follow-up programmes compared with standard care: the PRaCTICaL trial," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(3), pages 243-252, April.
  68. Zafar Hakim & Dev S. Pathak, 1999. "Modelling the EuroQol data: a comparison of discrete choice conjoint and conditional preference modelling," Health Economics, John Wiley & Sons, Ltd., vol. 8(2), pages 103-116, March.
  69. José Nunes, 1998. "Economic evaluation of rehabilitation: The quality of life approach using EuroQol," International Advances in Economic Research, Springer;International Atlantic Economic Society, vol. 4(2), pages 192-201, May.
  70. John N. Yfantopoulos & Athanasios E. Chantzaras, 2017. "Validation and comparison of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in Greece," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(4), pages 519-531, May.
  71. David G. T. Whitehurst & Stirling Bryan & Martyn Lewis, 2011. "Systematic Review and Empirical Comparison of Contemporaneous EQ-5D and SF-6D Group Mean Scores," Medical Decision Making, , vol. 31(6), pages 34-44, November.
  72. Josue Mbonigaba, 2012. "The Cost-effectiveness of Intervening in Low and High HIV Prevalence Areas in South Africa," Working Papers 304, Economic Research Southern Africa.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.